Fortress Biotech, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Lindsay A. Rosenwald, M.D. (CEO) and David Jin (CFO) issued standard Sarbanes-Oxley Sections 302 and 906 certifications for the Q2 2026 10-Q (period ended June 30, 2026) dated August 13, 2026. Both officers certified that the report complies with SEC requirements, contains no material untrue statements, and fairly presents financial condition and operations. No material weaknesses, significant deficiencies, or fraud disclosures are indicated in the certification language.
Why this rating
Routine SOX certifications; boilerplate disclosure required of all public companies. No material facts, transactions, control deficiencies, or fraud disclosed.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.